Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.
C. Chable-Bessia, C. Boulle, A. Neyret, J. M. Swain, M. Henaut, P. Merida, N. Gros, A. Makinson, S. Lyonnais, C. B. Chesnais, D. Muriaux
This study evaluates the anti-SARS-CoV-2 activity of ivermectin and other macrocyclic lactones in vitro, finding low selectivity indices that suggest limited therapeutic potential for COVID-19.
bioRxiv · Nov 1, 2021 · PreprintMicrobiology